D.A. Davidson & Co. Novo Nordisk A S Transaction History

D.A. Davidson & Co.

$13.8 Billion
Q2 2025

A detailed history of D.A. Davidson & Co. transactions in Novo Nordisk A S stock. As of the latest transaction made, D.A. Davidson & Co. holds 40,418 shares of NVO stock, worth $2.25 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

40,418

Previous 26,327 53.52%

Holding current value

$2.25 Million

Previous $1.83 Million 52.57%

% of portfolio

0.02%

Previous 0.02%

33 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Jul 30, 2025	BUY	$58.08 - $81.05 $818,405 - $1.14 Million	14,091 Added 53.52%	40,418 $2.79 Million
Q1 2025 Apr 28, 2025	SELL	$69.3 - $90.95 $419,403 - $550,429	-6,052 Reduced 18.69%	26,327 $1.83 Million
Q4 2024 Jan 31, 2025	SELL	$85.0 - $120.04 $1.6 Million - $2.26 Million	-18,833 Reduced 36.77%	32,379 $2.79 Million
Q3 2024 Nov 13, 2024	BUY	$119.07 - $145.42 $1.48 Million - $1.8 Million	12,399 Added 31.95%	51,212 $6.1 Million
Q2 2024 Jul 31, 2024	BUY	$122.71 - $146.91 $967,445 - $1.16 Million	7,884 Added 25.49%	38,813 $5.54 Million
Q1 2024 May 13, 2024	BUY	$102.11 - $135.92 $445,608 - $593,154	4,364 Added 16.43%	30,929 $3.97 Million
Q4 2023 Feb 09, 2024	BUY	$87.78 - $105.45 $274,663 - $329,953	3,129 Added 13.35%	26,565 $2.75 Million
Q3 2023 Nov 08, 2023	BUY	$90.94 - $199.54 $1.19 Million - $2.61 Million	13,080 Added 126.3%	23,436 $2.13 Million
Q2 2023 Aug 10, 2023	BUY	$155.98 - $172.65 $227,262 - $251,551	1,457 Added 16.37%	10,356 $1.68 Million
Q1 2023 Apr 25, 2023	SELL	$132.34 - $159.14 $38,775 - $46,628	-293 Reduced 3.19%	8,899 $1.42 Million
Q4 2022 Feb 03, 2023	BUY	$102.55 - $135.33 $44,916 - $59,274	438 Added 5.0%	9,192 $1.24 Million
Q3 2022 Nov 07, 2022	SELL	$95.28 - $116.93 $15,054 - $18,474	-158 Reduced 1.77%	8,754 $874,000
Q2 2022 Jul 28, 2022	BUY	$103.24 - $121.81 $21,370 - $25,214	207 Added 2.38%	8,912 $993,000
Q1 2022 May 12, 2022	BUY	$93.1 - $112.54 $54,929 - $66,398	590 Added 7.27%	8,705 $967,000
Q4 2021 Jan 31, 2022	BUY	$95.88 - $117.08 $212,757 - $259,800	2,219 Added 37.64%	8,115 $908,000
Q3 2021 Nov 15, 2021	BUY	$84.42 - $106.62 $50,652 - $63,972	600 Added 11.33%	5,896 $566,000
Q2 2021 Aug 10, 2021	BUY	$67.66 - $84.76 $7,104 - $8,899	105 Added 2.02%	5,296 $444,000
Q1 2021 May 07, 2021	BUY	$67.06 - $75.82 $3,353 - $3,790	50 Added 0.97%	5,191 $350,000
Q4 2020 Feb 10, 2021	SELL	$63.89 - $73.8 $47,917 - $55,350	-750 Reduced 12.73%	5,141 $359,000
Q3 2020 Nov 02, 2020	BUY	$63.69 - $70.22 $82,797 - $91,286	1,300 Added 28.32%	5,891 $409,000
Q2 2020 Aug 10, 2020	SELL	$58.54 - $67.94 $33,894 - $39,337	-579 Reduced 11.2%	4,591 $301,000
Q1 2020 May 05, 2020	SELL	$49.46 - $64.78 $6,330 - $8,291	-128 Reduced 2.42%	5,170 $311,000
Q4 2019 Feb 14, 2020	BUY	$49.86 - $58.26 $19,644 - $22,954	394 Added 8.03%	5,298 $307,000
Q3 2019 Nov 05, 2019	SELL	$47.54 - $53.43 $58,711 - $65,986	-1,235 Reduced 20.12%	4,904 $254,000
Q2 2019 Aug 13, 2019	SELL	$46.79 - $52.47 $256,970 - $288,165	-5,492 Reduced 47.22%	6,139 $313,000
Q1 2019 May 13, 2019	SELL	$46.36 - $52.63 $2.56 Million - $2.91 Million	-55,300 Reduced 82.62%	11,631 $608,000
Q4 2018 Jan 29, 2019	SELL	$41.54 - $47.25 $126,530 - $143,923	-3,046 Reduced 4.35%	66,931 $3.08 Million
Q3 2018 Nov 13, 2018	BUY	$46.76 - $51.24 $2,852 - $3,125	61 Added 0.09%	69,977 $3.3 Million
Q2 2018 Aug 02, 2018	SELL	$44.29 - $50.42 $72,635 - $82,688	-1,640 Reduced 2.29%	69,916 $3.23 Million
Q1 2018 May 04, 2018	BUY	$48.49 - $58.14 $124,910 - $149,768	2,576 Added 3.73%	71,556 $3.52 Million
Q4 2017 Feb 08, 2018	SELL	$47.53 - $53.73 $86,504 - $97,788	-1,820 Reduced 2.57%	68,980 $3.7 Million
Q3 2017 Nov 08, 2017	BUY	$41.15 - $49.22 $45,841 - $54,831	1,114 Added 1.6%	70,800 $3.41 Million
Q2 2017 Aug 11, 2017	BUY	N/A	69,686	69,686 $0

Others Institutions Holding NVO

# of Institutions

1,724

Shares Held

313M

Call Options Held

13.7M

Put Options Held

19.7M

View Full List

About NOVO NORDISK A S

Ticker NVO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,257,289,984
Market Cap $126B
Description
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...

More about NVO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D.A. Davidson & Co., based on Form 13F filings with the SEC.

News

Stay updated on D.A. Davidson & Co. with notifications on news.

Account